recent
advanc
develop
discoveri
pharmacolog
intervent
within
ubiquitinproteasom
system
up
uncov
enorm
potenti
possibl
novel
treatment
neurodegen
diseas
cancer
immunolog
disord
microbi
infect
interfer
proteasom
activ
although
initi
consid
unlik
exploit
clinic
alreadi
prove
effect
haematolog
malign
specif
deriv
target
subset
proteasom
emerg
recent
smallmolecul
screen
reveal
inhibitor
ubiquitinconjug
deconjug
enzym
mani
evalu
potenti
use
therapeut
either
singl
agent
synergi
drug
discuss
recent
advanc
characteris
novel
up
modul
particular
inhibitor
ubiquitinconjug
deconjug
enzym
pave
way
toward
new
therapeut
approach
treatment
proteotox
diseas
cancer
microbi
infect
ubiquitinproteasom
system
up
control
turnov
biolog
function
protein
within
cell
alter
process
contribut
cancer
progress
neurodegen
disord
pathogen
associ
microb
therefor
pharmacolog
target
up
potenti
provid
chemotherapeut
treatment
tumour
neurodegen
condit
infecti
diseas
widespread
involv
compon
up
mani
biolog
process
reflect
fact
sever
hundr
gene
associ
pathway
ref
ubiquitin
protein
amino
acid
coval
attach
protein
therebi
influenc
fate
function
protein
ubiquityl
numer
physiolog
function
act
recognit
signal
proteasom
degrad
polyubiquityl
serv
signal
scaffold
proteinprotein
interact
monoubiquityl
repres
target
signal
lysosom
pathway
cellular
compart
mostli
monoubiquityl
abil
ubiquityl
machineri
select
target
substrat
mediat
specif
ubiquitin
ligat
enzym
deconjug
promot
deubiquityl
enzym
dub
interfer
either
arm
pathway
allow
highli
target
pharmacolog
intervent
provid
compound
suffici
select
identifi
ref
fig
addit
opportun
provid
discoveri
pathogenencod
factor
evolv
target
up
host
cell
repres
attract
target
treatment
infecti
diseas
ref
therefor
up
offer
sourc
novel
pharmacolog
target
basi
success
develop
drug
treat
human
diseas
howev
complex
ubiquitin
system
caus
consider
challeng
highthroughput
drug
discoveri
extens
structur
similar
gener
select
inhibitor
also
imped
larg
number
dub
ref
ubiquitinconjug
enzym
ubiquitin
ligas
ref
might
redund
biolog
function
enzym
possess
affin
ubiquitin
variou
ubiquitin
conjug
therefor
specif
depend
structur
subtleti
differ
proteinprotein
interact
uniqu
enzym
speci
address
problem
array
methodolog
use
identif
hit
highthroughput
screen
ht
develop
suitabl
assay
function
screen
vitro
cell
use
protein
structur
aid
ration
drug
design
approach
alreadi
result
discoveri
panel
inhibitori
compound
proteasom
sever
ubiquitinconjug
enzym
dub
potenti
specif
drug
develop
discuss
target
proteasom
subset
inhibitionreduc
overal
toxic
overcom
drug
resist
protein
degrad
proteasom
multicatalyt
proteinas
complex
centr
up
pathway
fig
dub
also
molecular
target
inhibitor
develop
recent
year
fig
function
key
role
regul
receptor
endocytosi
traffick
prostaglandin
also
report
inhibitori
activ
dub
cellular
assay
famili
compound
form
group
lipid
deriv
serv
signal
molecul
affect
divers
protein
function
depend
localis
physiolog
context
prostaglandin
characteris
import
messeng
inflamm
ref
immun
respons
ref
emerg
role
cancer
jseri
prostaglandin
known
promot
apoptosi
fashion
ref
shown
inhibit
ubiquitin
isopeptidas
activ
cell
lysat
owe
presenc
crossconjug
keton
structur
fig
similarli
compound
unrel
prostaglandin
also
contain
crossconjug
keton
access
also
inhibit
isopeptidas
activ
contrast
aseri
prostaglandin
contain
singl
keton
less
efficaci
ubiquitin
isopeptidas
inhibitor
ref
henc
mechan
inhibit
jseri
prostaglandin
like
base
nucleophil
addit
dub
thiol
endocycl
compound
electrophil
access
prostaglandin
result
olefinketon
conjug
inhibitori
effect
prostaglandin
exemplifi
fig
compound
inhibit
activ
smallmolecul
inhibitor
deubiquityl
enzym
expert
review
molecular
medicin
cambridg
univers
press
fig
detriment
effect
structur
therefor
perturb
activ
offer
possibl
interf
progress
parkinson
diseas
associ
mutat
ref
punaglandin
cyclopentadienon
cyclopentenon
prostaglandin
chlorin
endocycl
posit
compound
origin
isol
telesto
riisei
coral
exhibit
antiinflammatori
antitumour
activ
ref
higher
cytotox
effect
cell
jseri
prostaglandin
interestingli
effect
apoptosi
independ
ref
consist
punaglandin
punaglandin
also
potent
inhibitor
cellular
dub
activ
jseri
prostaglandin
propos
mechan
enhanc
inhibitor
activ
presenc
electroneg
cl
substitu
carbonyl
increas
reactiv
toward
nucleophil
addit
dub
catalyt
cystein
thiol
group
chlorin
lipid
could
therefor
repres
new
class
cancer
therapeut
ref
inhibitor
base
molecular
scaffold
preferenti
specif
toward
uch
also
report
instanc
stein
colleagu
report
discoveri
isatin
oacyl
oxim
fig
ht
smallmolecul
compound
found
select
inhibitor
dub
associ
proteasom
block
degrad
ubiquityl
substrat
cellular
data
confirm
hypothesi
inhibit
indirectli
acceler
proteasom
degrad
protein
tau
involv
neurodegen
diseas
ref
mani
neurodegen
disord
parkinson
diseas
creutzfeldtjakob
diseas
associ
accumul
misfold
protein
fig
compound
smallmolecul
inhibitor
could
potenti
use
elimin
toxic
protein
improv
prognosi
neurodegen
diseas
support
previous
link
neurodegen
diseas
loss
lead
atax
neurolog
phenotyp
mice
ref
recent
addit
broadspecif
dub
inhibitor
fig
compound
discov
use
ubiquitinchop
report
technolog
ref
given
broad
specif
util
probabl
lie
role
tool
recov
ubiquityl
protein
cellfre
cellular
experiment
system
virus
also
encod
dub
target
block
viral
infect
papainlik
proteas
plpro
dub
encod
sever
acut
respiratori
syndrom
coronaviru
sarscov
ref
plpro
block
antivir
respons
indic
relev
key
infecti
process
viral
evas
host
innat
immun
respons
noncoval
inhibitor
plpro
fig
compound
block
sarscov
viral
replic
without
measur
cytotox
effect
henc
promis
antivir
drug
candid
induc
conform
chang
plpro
effect
inactiv
dub
profil
dub
activ
cell
expos
use
ubiquitinspecif
activesit
probe
demonstr
inhibitor
select
plpro
might
explain
low
cytotox
ref
summari
studi
illustr
potenti
mani
dub
suitabl
drug
target
sever
challeng
remain
recent
develop
novel
discoveri
platform
enzym
substrat
multiubiquitin
chain
differ
type
length
chop
report
technolog
isopeptidebondbas
assay
use
identifi
novel
dub
inhibitor
greater
specif
sensit
provid
framework
optimis
suitabl
drug
ubiquitin
ligas
repres
divers
group
protein
signific
role
ubiquitin
conjug
first
ligas
catalys
coval
transfer
ubiquitin
lysyl
side
chain
substrat
ref
second
specif
ligas
determin
substrat
becom
ubiquityl
base
recognit
signal
target
protein
ref
unsurprisingli
numer
function
neurodegen
disord
autoimmun
diseas
inflamm
cancer
ascrib
ligas
ref
one
crucial
ligas
cancer
cell
physiolog
protooncogen
murin
homologu
report
amplifi
mani
tumour
cell
ref
best
characteris
substrat
target
proteasom
thu
inhibit
lead
activ
pathway
provid
attract
therapeut
strategi
cancer
retain
wildtyp
express
crystal
structur
bound
peptid
reveal
deep
hydrophob
cleft
necessari
bind
featur
exploit
anticanc
treatment
ration
design
peptideand
nonpeptidebas
antagonist
interact
target
cleft
fig
compound
belong
class
tetrasubstitut
imidazolin
potent
nonpeptid
antagonist
act
competit
inhibitor
block
interact
ref
consequ
stabilis
substrat
noxa
contribut
increas
apoptosi
cell
cycl
arrest
phase
antitumour
properti
demonstr
cancer
cell
express
wildtyp
ref
effici
elimin
tumour
xenograft
mice
caus
measur
abnorm
anim
ref
preclin
studi
combin
proteasom
inhibitor
bortezomib
induc
addit
cytotox
malign
multipl
myeloma
cell
synergist
antitumour
activ
might
extend
clinic
applic
bortezomib
neoplasia
exhibit
reduc
sensit
proteasom
inhibitor
ref
analogu
current
phase
clinic
trial
treatment
solid
tumour
haematolog
malign
proofofconcept
data
provid
discoveri
nutlin
spur
addit
research
area
includ
identif
famili
compound
rita
fig
compound
also
target
ubiquitinligas
activ
result
activ
apoptosi
ref
addit
spirooxindol
exemplifi
fig
compound
chromenotriazolopyrimidin
also
report
effect
nonpeptidomimet
smallmolecul
inhibitor
interact
ref
anoth
mode
inhibit
block
associ
proteasom
fig
compound
one
first
compound
found
induc
level
tumour
cell
line
activ
transcript
activ
ref
current
investig
oral
agent
treatment
refractori
solid
tumour
clinic
trial
natur
product
also
import
sourc
novel
ligas
inhibitor
exampl
microbi
extract
deriv
ferment
microorgan
actinomycet
bacteria
fungi
screen
discov
new
compound
antagonis
interact
among
chlorofusin
fig
compound
fungal
metabolit
isol
fusarium
sp
found
highest
chalcon
specif
interfer
interact
ref
thalidomid
inhibitori
activ
toward
ref
chlorofusin
nineresidu
cyclic
peptid
contain
lornithin
side
chain
link
highli
functionalis
tricycl
chromophor
studi
establish
neither
cyclic
peptid
chromophor
chlorofusin
alon
simpl
deriv
thereof
account
inhibit
interact
whole
structur
chlorofusin
requir
ref
second
exampl
natur
product
exhibit
inhibit
interact
enantiom
hexylitacon
acid
isol
cultur
marinespongederiv
fungu
arthrinium
sp
ref
hexylitacon
acid
impair
interact
dosedepend
manner
deriv
includ
monomethyl
ester
dihydro
deriv
dihydro
deriv
monomethyl
ester
show
inhibitori
activ
chalcon
aromat
keton
previous
characteris
potenti
antitumourigen
therapeut
ovarian
cancer
ref
gastric
cancer
tumour
ref
chalcon
deriv
interfer
interact
bind
near
tryptophanbind
pocket
hydrophob
cleft
ref
molecular
model
studi
indic
boron
acid
bind
lysin
residu
ref
detail
mechan
cytotox
activ
chalcon
remain
determin
case
enhanc
apoptosi
relat
inhibit
proteasom
thu
stabilis
exemplifi
boron
chalcon
deriv
fig
compound
ref
regardless
seem
like
chalconemedi
inhibit
interact
contributori
mechan
report
antitumour
properti
ref
ubiquitin
ligas
constitut
potenti
therapeut
target
scf
scf
sphase
kinaseassoci
protein
ubiquitin
ligas
contain
fbox
protein
determin
substrat
specif
upregul
scf
associ
decreas
level
neg
correl
good
prognosi
cancer
ref
therefor
compound
directli
target
scf
repres
potenti
drug
cancer
therapi
use
ht
chen
colleagu
identifi
compound
cpda
promis
scf
inhibitor
prevent
incorpor
fbox
protein
scf
ligas
complex
cpda
thu
lead
ubiquitindepend
accumul
substrat
scf
ligas
activ
consequ
induc
cell
cycl
arrest
apoptosi
notabl
cpda
work
synergist
proteasom
inhibitor
bortezomib
ref
probabl
interf
neddyl
recent
two
addit
exampl
inhibitor
report
first
use
fluoresc
polaris
screen
biplanar
dicarboxyl
acid
compound
shown
alloster
inhibitor
substrat
recognit
yeast
fbox
protein
scf
scf
degrad
mani
substrat
phosphorylationdepend
manner
inhibitor
perturb
phosphodegron
bind
pocket
scf
ref
second
group
use
yeastbas
chemic
genet
screen
identifi
modul
scf
activ
ref
biochem
studi
confirm
specif
inhibit
scf
depend
ubiquityl
transcript
factor
reduc
bind
probabl
due
direct
bind
cereblon
crbn
damag
dnabind
protein
form
ligas
complex
import
embryon
develop
complex
target
thalidomid
fig
compound
clinic
approv
drug
treatment
multipl
myeloma
leprosi
inflammatori
bowel
diseas
crohn
diseas
ref
one
enantiom
thalidomid
found
teratogen
side
effect
bind
thalidomid
crbn
complex
inhibit
crbn
ligas
activ
appear
underli
molecular
mechan
thalidomideinduc
teratogen
perturb
embryon
develop
ref
key
effector
enzym
muscular
atrophi
area
unmet
medic
need
sever
differ
patholog
ref
use
elisabas
ht
platform
progenra
identifi
novel
modul
ubiquitin
ligas
inhibit
autoubiquityl
myosin
heavychain
ubiquityl
protect
myotub
dexamethasoneinduc
muscl
wast
ref
outlin
identifi
ligas
inhibitor
direct
toward
proteinprotein
interact
druggabl
therefor
challeng
complex
enzym
famili
lack
detail
precis
molecular
mechan
fact
reli
proteinprotein
interact
mediat
activ
make
design
ligas
inhibitor
difficult
ref
potenti
offer
framework
translat
applic
interf
mani
differ
biolog
process
highli
specif
manner
recent
report
identif
specif
scf
inhibitor
increas
confid
possibl
develop
inhibitor
emerg
class
import
drug
target
ubiquitin
conjug
requir
initi
activ
ubiquitin
enzym
adenyl
ctermin
carboxyl
group
ubiquitin
form
highenergi
ubiquitin
adenyl
intermedi
follow
format
thiol
ester
carboxyl
group
ubiquitin
thiol
group
seri
reaction
activ
cterminu
ubiquitin
subsequ
nucleophil
attack
ref
block
reaction
could
therefor
use
inhibit
ubiquitin
conjug
vitro
studi
suggest
knockdown
ligas
result
lower
level
protein
ubiquityl
eventu
induc
cell
death
malign
cell
ref
identifi
novel
inhibitor
yang
colleagu
screen
librari
small
compound
identifi
benzoic
acid
ethyl
ester
first
cellperm
inhibitor
effici
reduc
bulk
protein
ubiquityl
sumoyl
prevent
degrad
contribut
enhanc
apoptosi
also
attenu
cytokinemedi
nuclear
activ
regul
proteasom
degrad
inhibitori
subunit
function
probabl
bind
irrevers
activesit
cystein
ligas
therefor
prevent
ubiquitin
transfer
ref
howev
compound
also
target
sever
dub
includ
crosslink
kinas
antitumour
activ
anim
ref
fig
compound
anoth
smallmolecul
inhibitor
shown
interfer
activ
ligas
preferenti
induc
tumour
cell
death
primari
acut
myeloid
leukaemia
cell
effect
also
studi
mous
model
leukaemia
reduc
tumour
weight
volum
studi
underlin
import
potenti
drug
target
leukaemia
possibl
cancer
especi
case
neoplast
cell
resist
treatment
proteasom
inhibitor
bortezomib
ref
furthermor
two
natur
product
identifi
inhibit
panepophenanthrin
isol
mushroom
panu
rudi
ref
himeic
acid
deriv
fungu
aspergillu
sp
ref
inhibit
ubiquitin
activ
vitro
unknown
mechan
recent
smallmolecul
inhibitor
enzym
also
discov
leucettamol
compound
isol
marin
spong
leucetta
aff
microrhaphi
identifi
novel
inhibitor
interact
therebi
block
format
complex
ref
also
alloster
inhibitor
human
ligas
found
smallmolecul
screen
inhibitor
scf
depend
ubiquityl
shown
interfer
prolifer
human
cancer
cell
line
ref
gener
target
conjug
enzym
sever
pathway
depend
ubiquityl
dna
repair
endocytosi
inhibit
time
potenti
contribut
increas
nonspecif
cytotox
therefor
therapeut
standpoint
use
ubiquitin
specif
inhibitor
current
await
addit
preclin
valid
advanc
clinic
studi
given
scf
ligas
repres
sever
hundr
known
ubiquitin
ligas
concern
inhibit
ligas
might
lead
seriou
side
effect
clinic
set
howev
impact
side
effect
must
taken
context
proteasom
inhibitor
shown
exhibit
accept
clinic
profil
treatment
cancer
yet
modul
stabil
mani
protein
rel
scf
ultim
evalu
successor
compound
clinic
set
determin
whether
strategi
therapeut
accept
approach
ubiquitin
system
ubiquitom
compar
wellcharacteris
kinom
spur
entir
array
novel
inhibitor
molecular
target
manipul
ubiquitin
ubiquitinlik
molecul
similarli
kinas
field
function
redund
structur
similar
activ
site
dub
divers
proteinprotein
interact
domain
conjug
enzym
render
discoveri
specif
inhibitor
challeng
sever
novel
compound
promis
result
clinic
trial
proteasom
inhibitor
carfizomib
phase
iii
phase
phase
nae
inhibitor
phase
aml
solid
tumour
thalidomid
clinic
use
mani
year
recent
identifi
ligas
inhibitor
also
sever
ligas
inhibitor
compound
prove
success
preclin
stage
gener
remain
determin
whether
small
molecul
requir
specif
target
one
molecul
clinic
use
whether
manner
similar
medic
relev
kinas
inhibitor
molecul
broader
specif
subfamili
enzym
might
exhibit
clinic
efficaci
clearli
emerg
new
inhibitor
direct
up
compon
supplement
activ
kinas
inhibitor
cytotox
agent
compound
predict
ultim
combinatori
use
drug
hold
greatest
promis
futur
therapi
cancer
neurodegen
disord
infecti
diseas
diseas
patholog
highli
complex
substanti
differ
occur
individu
broaden
arsen
smallmolecul
compound
includ
drug
target
compon
up
might
provid
framework
individualis
drug
regimen
part
trend
toward
personalis
medicin
gener
understand
precis
role
ligas
dub
compon
up
diseas
process
establish
correl
dysfunct
properti
diseas
patholog
develop
promis
lead
compound
effect
inhibitor
greater
potenc
wherea
mani
smallmolecul
compound
show
antiprolif
activ
tumour
cell
expert
review
http
wwwexpertreviewsorg
molecular
medicin
line
less
clear
translat
inhibit
tumour
growth
vivo
without
affect
normal
cell
distinguish
two
scenario
drive
select
develop
effect
compound
futur
realli
necessari
chemic
target
one
enzym
optim
interfer
diseas
progress
mani
diseas
particular
cancer
exert
aberr
sever
biochem
pathway
discoveri
pharmacolog
target
abnorm
function
network
necessari
better
treatment
futur
featur
associ
articl
